Just last September, Cancer Treatment Centers of America made health headlines by providing free and reduced cost prostate screens for promotion of preventative health tests now recommended for men. This well known cancer organization partnered with other interested in helping groups to provide this valuable health service. Many men die to prostate cancer every year. Many others are limited sexually and have frequent difficulty with urination. Often, the prostate becomes enlarged as a man ages. Prostate cancer should be ruled out early on to prevent unnecessary deaths and suffering. Prostate cancer can be treated effectively, relatively easily and often successfully when the diagnosis is made early in the disease process.
Cancer Treatment Centers of America has been a strong supporter of cancer screening as part of their preventative health promotion efforts. They treat adult men and women diagnosed with cancer, and this organization is invested in ongoing clinical and cancer research trials to find more treatments and cure many various cancer forms. Prostate cancer is a high occurring cancer for men. The number of cases rises as males get older. These gentlemen should seek medical treatment with any signs of urination or sex problems. Safe and simple prostate screens can detect prostate cancer early even if the individual isn’t noticing any problem symptoms.
With attention on preventative health these days, more people and their physicians are open and supportive of preventative health measures. Cancer Treatment Centers of America is continuing to provide essential cancer treatments and preventative or early diagnostic cancer tests and screens. These tests are not uncomfortable or time consuming. Every man should speak with their family doctor about this devastating disease. There are things that can be done to help slow and prevent the occurrence of this fast spreading cancer. Find out more online or call CTCA.
Healthcare costs are increasing in the United States. Americans paid $933 billion more on healthcare in 2013 than they did merely 17 years before that in 1996. They can blame the cost increases on care fees that are higher than ever before. They can blame the increases on medical care that’s markedly more in-depth as well.
The population is expanding. Members of the population are getting older, too. These are other elements that contributed to the significant spike in spending. Numerous components are behind the serious change. Diabetes is one of them. This medical condition was associated with a substantial boost in spending on an annual basis. Pharmaceutical costs are also a big culprit.
Eric Paul Lefkofsky is a prominent individual who established Tempus, a renowned technology firm. Tempus is in the process of constructing the biggest clinical and molecular data network on the planet. It’s in the process of constructing an in-depth operating system that aims to streamline data access as well. Eric Lefkofsky has been on this planet since September of 1969. This esteemed entrepreneur functions as Tempus’ diligent CEO (Chief Executive Officer). He’s married to a woman who is called Elizabeth.
Lefkofsky has had a long and fulfilling career so far. He started out by handling carpet sales while a young student at the University of Michigan located in Ann Arbor, Michigan. He completed law school. Once he was through with law school, he asked family members for a loan. That’s precisely when he made the decision to purchase a Madison, Wisconsin-based clothing brand. The brand was called Brandon Apparel. He purchased it alongside a pal he made in college. This was Brad Keywell.
Lefkofsky is an individual who has a commitment to entrepreneurship that’s matchless in intensity. He’s also a person who has a strong penchant for philanthropy work of all kinds. He set up a charitable trust in 2006. He did this with his wife. They named the trust “The Lefkofsky Foundation.” The aim in establishing this foundation was to help educational, science and charitable causes and groups from all different corners of the globe.
To know more click here
Dr. Mikhail Blagosklonny is amongst the medical professionals who are on the forefront of battling cancer. A professor of Oncology at New York’s Roswell Park Cancer Institute, he is well known for his support of using the drug Rapamycin, also known as Sirolimus, to slow down the aging process. Rapamycin is also used to contain numerous conditions as Mikhail Blagosklonny has discovered through his various researches.
Uses of Rapamycin
Dr. Mikhail’s research on the use of Rapamycin has led him to discover various healing properties of the drug.
- Coronary Stent Coating. After a balloon angioplasty procedure, rapamycin can be applied to the arteries to prevent restenosis. Studies on patients who used the drug showed that very few of them complained of restenosis. Thus, they didn’t have a need to redo the procedure more often.
- Immunosuppressant. The body is designed to reject transplanted. Nonetheless, if that were to be allowed, operations would be unsuccessful. Doctors, therefore, use anti-rejection drugs. However, rapamycin has been found to be the best option as it has the least amounts of toxicity and other side effects to the organs.
- Used in cancer treatment. It has been established that when cancer patients take the right measures of Sirolimus, their immune systems get boosted. Eventually, it also prevents tumors from worsening. Use of the drug can also prevent new organs from getting the disease.
- Treating Tuberous Sclerosis Complex (TSC). Anyone with TSC congenital disorder is at risk of developing benign tumors in critical organs like the heart or even brain. In a study, use of rapamycin saw TSC get blocked. Stoppage of the medication resulted in the tumors growing again.
These are just but a few of the benefits of rapamycin as revealed by Dr. Mikhail Blagosklonny. He is still involved in current research about Sirolimus and how it can be used to extend human lifespan.
Dr. Blagosklonny’s Future Plans for Oncology
A renowned professor, researcher, and philanthropist, Mikhail Blagosklonny has a mission to ensure every individual has access to the best cancer treatment regardless of wealth status or location. He has nonetheless committed a better part of his research to both aging and cancer.Mikhail Blagosklonny is fixed on finding not only a cure for cancer, but he wants the experience of the treatment to be much better than it is now. Instead of the high costs and painful procedures, Mikhail hopes to find a cure that does not involve the destruction of other cells that are crucial to the recovery process. He also hopes that cancer treatment will be affordable for everyone, and not just for the high and mighty.
About Mikhail Blagosklonny
For school, Mikhail Blagosklonny went to St. Petersburg’s First Pavlov State Medical University, where he earned an MD in Internal Medicine, as well as a Ph.D. in Experimental Medicine and Cardiology. He had a role as Senior Scientist at Ordway Research Institute, before becoming Professor of Oncology at the Roswell Park Cancer Institute. He is also Editor-in-chief of Oncotarget and is on the journalist’s editorial board of Cell Death and Differentiation.
Mikhail Blagosklonny is a doctor who works for Oncotarget. He has a position with the Rosewell Park Cancer Institute located in Buffalo, New York. He serves as an oncology professor for the educational institution. He has performed substantial research that pertains to cancer and all of its treatments and therapeutic approaches. Blagosklonny has a lot on his plate with Oncotarget as well. He’s Oncotarget’s proud editor-in-chief and has been at the helm of a lot of in-depth research that involves the aging process. Blagosklonny has a reputation in the cancer world as well. People who make up the cancer community know that he supports Rapamcyin. This is a cancer drug that Blagosklonny believes has the ability to give the human lifespan a significant boost. There’s no disputing that Blagosklonny has done a lot for the science world, to say the least. Many people have no idea what Rapamycin does. This medicine, however, is associated with a variety of different things. It has immunosuppressant abilities, first and foremost. It can treat individuals who suffer from a condition that’s known as hemolytic-uremic syndrome. It can help LAM (Lymphangioleiomyomatosis) sufferers.
Other benefits that are linked to Rapamcyin are better longevity, coronary stent coating and muscular dystrophy treatment.Blagosklonny is the type of person who takes on many diverse roles on a daily basis. He’s more than just a professor and doctor. He’s also a dedicated philanthropist who cares a lot about giving anything he can to other people. One of Blagosklonny’s top aims in life is to give other people access to high-quality treatments. He doesn’t want people who don’t have a lot of money to have to worry about how they’re going to cover their medical treatments. Medical research is a subject that’s close to Blagosklonny’s heart. His research zeroes in on aging and cancer. He has a passion that involves the relationship between aging and cancer as well. Blagosklonny wants to understand why cancer is particularly prevalent in elderly persons. The disease just isn’t as widespread in younger people.
This expert wants to treat cancer more than anything else. He has a wish that goes beyond that, too. Blagosklonny strives day in and day out to determine how to provide members of the general public with cancer treatment options that honestly do not cost a fortune. Modern cancer treatments tend to cost a substantial sum of money. That’s the reason modern cancer treatments can be such an enormous source of frustration for people. Blagosklonny dreams about coming up with a solution that enables the destruction of cancerous cells within the body. He wishes to promote cancerous cell destruction without the eradication of healthy cells. People who have cancer need to possess healthy cells that can be beneficial for the time-consuming healing process. Cancer treatment can in many cases take a significant toll on the body and brain. People need to have normal cells that can assist them with all different aspects of recovery and getting better. Blagosklonny’s cancer treatment enthusiasm is unparalleled.
There have been many advances in cancer, but it has been hard for all oncologists to get them and to be able to use them for different situations because of all of the issues that come along with the experiences that they have. It has been a struggle for most people, but it has not always worked out because of the issues that come along with a lack of communication in oncology field. Mikhail Blagosklonny knew this because he is a part of the oncology field and because he worked hard to be able to show people what they can do to make their lives better while they are battling cancer.One thing that he always hoped for in the field was better communication. He wanted there to be some type of peer review or publication that would make things better for doctors to learn more about cancer what was going on or what they could do to help their patients.
He knew that other oncology specialists had them, but he also knew that he wanted to be able to make sure that he could help his own type of patients out with the issues that they had. For Mikhail Blagosklonny to do this, he had to be sure that the oncologists in the country could connect with each other.The answer that he was looking for came in the form of a peer review publication. Since there wasn’t one that was geared specifically toward oncologists, he decided to just start one on his own. He tried his best to start Oncotarget and he knew that he would be able to make a difference with the publication. For that reason, he did his best to show people what they were going to get from it so that they could help their patients in the same way that other oncologists were able to help their own patients.
Out of all of the things that Mikhail Blagosklonny was doing, he knew that he could try his best and show people what would make a difference. He tries to always include new advancements into the Oncotarget publication, but he sometimes has to get other doctors on board so that he will be able to help even more people. Not just oncologists can come up with treatment for cancer and he knows that the help of other doctors will be something that he can enjoy.As things have gotten better for Mikhail Blagosklonny and the publication has grown, he has been showing people what they can do and how they can get more out of the situations that they are in. This is what has given him a chance to experience more and to try more opportunities out with the things that are going on. It has also given him a chance to grow the industry and make it better than what it was in the past for cancer patients to feel better and to be able to be healed from their disease that they are battling.
When Eric Lofkosfky left Groupon, he began building up the newly launched firm, Tempus. Tempus is a modern day cancer treatment facility that uses high-tech devices to diagnose and treat cancer. Tempus’ medical practitioners use real-time and customized data–based therapy machines to analyze each patient’s genetic makeup. They then use the results to determine the best molecular therapies for the particular cancer type ailing the candidate. The technology helps patients understand a patient’s tumor better to create a most suitable medication using massive amounts of statistical genomic data. The company separated itself from its parent company LightBank, which is also owned by Eric. Eric is currently serving as Tempus’ president and believes that the firm can develop next breakthrough in medicine world.
On July 18th, 2016, Eric wrote about how data collection and artificial intelligence propel the society forward in medicine. He explained the various ways that health care has reached milestones in developing new technology. In 2003, Tempus produced the first human genome with over 100 million dollars. After only 13 years they, processed the same procedure with only 5000 dollars. He estimates that in a few more years, it will be available for just a few hundred dollars. The system allows physicians to tailor the necessary treatments medicine rations for all cancers. Currently, Tempus has an employee capacity of 29, including the former director of products At HighGround, Hunter Lane and Lightbank’s former vice president, Ryan Fukushima.
Eric and his wife Liz are regular donors to the cancer research treatment movement through their organization Lofkosfky Family Foundation. In November 2016, they contributed 1 million dollars to the Robert Lurie Comprehensive Cancer Center of the Northwestern University. In October of the same year, they donated $500,000 to the development of immunotherapy gastric cancer at the Stanford University. They contributed 1.2 million dollars to cancer research at the University of Michigan. The New York Weill Cornell Medicine Foundation received $250,000 from the couple to treat breast cancer. Eric and his wife are members of The Giving Pledge and have a pledge to donate half of their wealth to philanthropy at the end of their lifetimes.
for more info: www.tempus.com/about-us/